Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Learn more about:
Related Clinical Trial
Optimising Molecular Radionuclide Therapy Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer Function Integrity of Neck Anatomy in Thyroid Surgery An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Evaluation of a New CZT System Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain A Study Into the Effect of Seprafilm in Open Total Thyroidectomy Lenvatinib and Pembrolizumab in DTC Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Influence of Thyroid Hormones on the Woundhealing Process ctDNA in Patients With Thyroid Nodules Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine Trial of LBH589 in Metastatic Thyroid Cancer Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma Thyroid Cancer and Sunitinib Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Lipid Metabolic Status in Thyroid Carcinoma

Brief Title

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Official Title

A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction

Brief Summary

      This phase I trial studies the side effects and best dose of romidepsin in treating patients
      with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
      Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking
      the activity of proteins that are important for the cancer's growth and survival.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To establish the safety and tolerability of romidepsin given on days 1, 8, and 15 of a 28
      day cycle to patients with varying degrees of liver dysfunction (mild, moderate and severe).

      II. To establish the maximum tolerated dose (MTD) and appropriate dosing recommendations for
      romidepsin in such patients.

      III. To characterize the pharmacokinetics (PK) of romidepsin in patients with varying degrees
      of liver dysfunction.

      SECONDARY OBJECTIVES:

      I. To explore correlations of the Child-Pugh classification of liver dysfunction with the
      observed toxicities and plasma PK of romidepsin administration.

      II. To document any preliminary evidence of antitumor activity at tolerable doses of
      romidepsin in patients with varying degrees of liver dysfunction.

      OUTLINE: This is a dose-escalation study.

      Patients receive romidepsin intravenously (IV) over 4 hours on days 1, 8, and 15. Courses
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0

Secondary Outcome

 Child-Pugh classification of hepatic dysfunction

Condition

Glioma

Intervention

Pharmacological Study

Study Arms / Comparison Groups

 Treatment (romidepsin)
Description:  Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

37

Start Date

June 12, 2012


Primary Completion Date

November 29, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed (at original diagnosis or
             subsequent recurrence or progression) lymphoma, chronic lymphocytic lymphoma (CLL) or
             solid tumor; patients with lymphoma or CLL must have radiologically or clinically
             evaluable disease, and be refractory to standard therapy as defined by relapse within
             6 months of last treatment (see note below); patients with solid tumors must have
             radiologically or clinically evaluable disease that is metastatic, unresectable,
             progressive, or recurrent, and for which standard curative measures do not exist or
             are no longer effective

               -  Patients with a liver mass, raised alpha-fetoprotein level (>= 500 ng/mL) and
                  positive serology for hepatitis, consistent with a diagnosis of hepatocellular
                  carcinoma will be eligible without the need for pathologic confirmation of the
                  diagnosis

               -  Patients with prostate cancer, renal cell cancer, neuroendocrine tumors, lung
                  cancer, colorectal cancers, soft tissue sarcomas, glioma and thyroid cancer are
                  excluded in the normal and mild cohorts due to a lack of efficacy in these tumor
                  types in phase 2 studies; patients with breast, pancreatic, bladder, head and
                  neck cancers, as well as melanoma and other malignancies are eligible

               -  Note: patients with prostate cancer, renal cell cancer, lung cancer, colorectal
                  cancers, soft tissue sarcomas, glioma and thyroid cancer are allowed to enroll in
                  the moderate and severe cohorts provided the patients:

                    -  Sign a separate consent form which outlines the lack of efficacy observed in
                       prior studies

                    -  Are consented to the study by a protocol-specified designee who is not their
                       longitudinal oncologist; patients with neuroendocrine tumors are still
                       excluded from the moderate and severe cohorts

               -  Note: as romidepsin is approved for patients with relapsed or refractory
                  peripheral T-cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL), these
                  patients would be eligible WITHOUT the requirement of having 'relapsed within 6
                  months of last treatment'

          -  Life expectancy of > 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

          -  Hemoglobin >= 9 g/dL (transfusions and/or erythropoietin are permitted)

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

          -  Platelets >= 100 x 10^9/L (or platelet count >= 30 x 10^9 cells/L in patients with
             lymphoma or CLL if bone marrow disease involvement is documented)

          -  Creatinine =< twice upper limit institutional normal

          -  Patients with abnormal liver function will be eligible and will be grouped according
             to the criteria below

               -  Group A (normal hepatic function)

                    -  Bilirubin =< upper limit of normal (ULN) and aspartate aminotransferase
                       (AST) =< ULN

               -  Group B (mild hepatic dysfunction)

                    -  B1: bilirubin =< ULN and AST > ULN

                    -  B2: bilirubin > ULN but =< 1.5 x ULN and any AST

               -  Group C (moderate hepatic dysfunction)

                    -  Bilirubin > 1.5 x ULN to =< 3 x ULN and any AST

               -  Group D (severe hepatic dysfunction)

                    -  Bilirubin > 3 x ULN and up to investigators discretion and any AST

               -  Patients with active hemolysis should be excluded; no distinction will be made
                  between liver dysfunction due to metastases and liver dysfunction due to other
                  causes; registration laboratory investigations will be used to assign a patient
                  to a hepatic function group; liver function tests should be repeated within 24
                  hours prior to starting initial therapy and may result in the patients' group
                  assignment being altered if different to registration test results

          -  Patients with brain metastases who require corticosteroids or non-enzyme inducing
             anticonvulsants must be on a stable dose of corticosteroids and seizure free for 1
             month prior to enrollment; patients with known brain metastases should have completed
             brain irradiation (whole brain or gamma knife) more than 4 weeks before starting the
             protocol; patients on enzyme inducing anticonvulsants are not eligible; note that
             patients should have had their steroids tapered to low dose (i.e. < 1.5 mg of
             dexamethasone/day) due to the potential for higher dexamethasone doses to induce
             CYP3A4

          -  Patients with biliary obstruction for which a stent has been placed are eligible,
             provided the shunt has been in place for at least 10 days prior to the first dose of
             romidepsin and the liver function has stabilized; two measurements at least 2 days
             apart that put the patient in the same hepatic dysfunction stratum will be accepted as
             evidence of stable hepatic function; there should be no evidence of biliary sepsis

          -  Eligibility of patients receiving any medications or substances known to affect or
             with the potential to affect the activity or PK of romidepsin will be determined
             following review of their case by the site principal investigator

               -  Patients treated with any of the medications prohibited must discontinue their
                  use at least 7 days prior to the first dose of romidepsin; certain other agents
                  that interact with the CYP3A4 system may be used with caution

          -  Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately; note: since romidepsin binds to the estrogen receptor, the effectiveness
             of estrogen containing contraceptives may be reduced

          -  Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents
             with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals
             (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine,
             emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor
             (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir,
             maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients
             should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause
             of hepatic dysfunction is unknown, the patient should be worked up for other viral
             causes of hepatitis and their eligibility determined after consultation with the
             principal investigator

          -  Patients who have received prior romidepsin use are eligible

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had (prior to entering the study): major surgery and
             biologic/antibody therapies (including immunotherapies) are not permitted within 4
             weeks of romidepsin administration; anti-cancer therapy including chemotherapy,
             radiotherapy, hormonal (with the exception of hormones for thyroid conditions), and
             other investigational agents will not be allowed within 14 days or five (5) half-lives
             (whichever is longer) prior to the first dose of romidepsin (6 weeks for nitrosoureas
             or mitomycin C); additionally, participants must have recovered to less than grade 2
             clinically significant adverse effect(s)/toxicity(ies) of the previous therapy, with
             the exception of alopecia, unless approved by the principal investigator

          -  Patients with prostate cancer, renal cell cancer, neuroendocrine tumors, lung cancer,
             colorectal cancers, soft tissue sarcomas, glioma, and thyroid cancer are excluded in
             the normal and mild cohorts due to a lack of efficacy in these tumor types in phase 2
             studies; patients with prostate cancer, renal cell cancer, lung cancer, colorectal
             cancers, soft tissue sarcomas, glioma and thyroid cancer are allowed to enroll in the
             moderate and severe cohorts only; patients with neuroendocrine tumors are still
             excluded from the moderate and severe cohorts

          -  Patients may not be receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to romidepsin, including cyclic tetrapeptide compounds

          -  Concurrent medications associated with a known risk of corrected QT interval (QTc)
             prolongation and/or Torsades de Pointes are not allowed within 2 weeks of initiation
             of study treatment; those medications listed as a possible risk for causing QTc
             prolongation and Torsades de Pointes will be allowed, although if an alternative
             medication can be substituted, that would be preferable; granisetron is an acceptable
             antiemetic on this study, but if a patient must take ondansetron, they may NOT take
             any other concomitant agents which might impact their QTc

          -  Thiazolidinedione agents such as rosiglitazone and pioglitazone are not permitted

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Patients with current evidence of significant cardiovascular disease (New York Heart
             Association class III or IV cardiac disease), symptomatic congestive heart failure,
             dilated/hypertrophic or restrictive cardiomyopathy, myocardial infarction (within the
             past 6 months), unstable angina, unstable arrhythmia or a need for anti-arrhythmic
             therapy (use of medications for rate control for atrial fibrillation is allowed such
             as calcium channel blockers and beta-blockers, if stable medication for at least last
             month prior to initiation of romidepsin treatment and medication not listed as causing
             Torsades de Pointes), or evidence of acute ischemia on electrocardiogram (ECG); marked
             baseline prolongation of QT/QTc interval, e.g., repeated demonstration of a QTc
             interval > 450 msec*; long QT syndrome; the required use of concomitant medication
             that may cause Torsades de Pointes or may cause a significant prolongation of the QTc

               -  Note: due to difficulties assessing QTc in patients with heart block, they may be
                  eligible if deemed safe by a cardiologist; if a patient must take ondansetron as
                  their antiemetic, their QTc may NOT be over 450 (no exception for patients with
                  heart block)

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with this drug

          -  Warfarin is not permitted
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Roisin M Connolly, , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT01638533

Organization ID

NCI-2012-01040

Secondary IDs

NCI-2012-01040

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)

Collaborators

 Celgene Corporation

Study Sponsor

Roisin M Connolly, Principal Investigator, JHU Sidney Kimmel Comprehensive Cancer Center LAO


Verification Date

May 2021